All In Biotech

Investigational drug · Phase 2

Vebeglogene autotemcel

Also called: Beta-globin lentiviral vector transduced autologous HSPCs

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Beta-Thalassemia.

Phase 2

Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "Vebeglogene autotemcel"

First trial start

2024

May 11, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Vebeglogene autotemcel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Beta-Thalassemia

Approved drugs for the same conditions: Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Vebeglogene autotemcel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Beta-Thalassemia

  • BRL-101Phase 21 trial

    Bioray Laboratories · Beta-Thalassemia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.